Enterprise Value
193.7M
Cash
341.3M
Avg Qtr Burn
N/A
Short % of Float
21.79%
Insider Ownership
4.02%
Institutional Own.
33.89%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
OMIDRIA (phenylephrine and ketorolac intraocular solution) Details Cataract surgery or intraocular lens replacement | Approved Quarterly sales | |
Narsoplimab (MASP-2 inhibitor, lectin pathway) Details Rare diseases, Blood disorder | Phase 3 Data readout | |
Narsoplimab (OMS721) (MASP-2 inhibitor, lectin pathway) Details Hematopoietic cell transplantation | Phase 3 Data readout | |
OMS405 (PPARγ agonist) Details Addiction | Phase 2 Data readout | |
OMS1029 (MASP-2) Details Lectin pathway disorder | Phase 2 Data readout | |
OMS527 (PDE7 inhibitor) Details Movement disorder, Levodopa-induced dyskinesia associated with Parkinson’s disease, Cocaine use disorder, Addiction | Phase 2 Update | |
OMS906 Details Paroxysmal nocturnal hemoglobinuria , Blood disorder | Phase 1b Data readout | |
Narsoplimab (MASP-2 inhibitor, lectin pathway) Details Kidney disease, Diabetic macular edema, Diabetes | Failed Discontinued | |
Narsoplimab (MASP-2 inhibitor, lectin pathway) Details Kidney disease, IgA nephropathy | Failed Discontinued |